JPH11511738A - 抗マラリア性有機金属鉄錯体 - Google Patents
抗マラリア性有機金属鉄錯体Info
- Publication number
- JPH11511738A JPH11511738A JP8533842A JP53384296A JPH11511738A JP H11511738 A JPH11511738 A JP H11511738A JP 8533842 A JP8533842 A JP 8533842A JP 53384296 A JP53384296 A JP 53384296A JP H11511738 A JPH11511738 A JP H11511738A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- complex
- ferrocene
- hydrogen
- hydroxyalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 organometallic iron complex Chemical class 0.000 title claims abstract description 19
- 230000000078 anti-malarial effect Effects 0.000 title claims abstract description 14
- 239000003430 antimalarial agent Substances 0.000 title description 9
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical group [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 claims abstract description 21
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical group [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 19
- 150000001875 compounds Chemical class 0.000 claims description 28
- 125000000217 alkyl group Chemical group 0.000 claims description 19
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 239000001257 hydrogen Substances 0.000 claims description 14
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 10
- 125000002524 organometallic group Chemical group 0.000 claims description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 9
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 claims description 8
- 125000002252 acyl group Chemical group 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical group 0.000 claims description 8
- 201000004792 malaria Diseases 0.000 claims description 8
- 125000005041 acyloxyalkyl group Chemical group 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 5
- 150000001412 amines Chemical group 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 3
- 235000002906 tartaric acid Nutrition 0.000 claims description 3
- 239000011975 tartaric acid Substances 0.000 claims description 3
- 125000004423 acyloxy group Chemical group 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 5
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 abstract description 8
- 235000001258 Cinchona calisaya Nutrition 0.000 abstract description 4
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 abstract description 4
- 229960000948 quinine Drugs 0.000 abstract description 4
- 230000000694 effects Effects 0.000 description 12
- 244000045947 parasite Species 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 229910052742 iron Inorganic materials 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 5
- 150000001299 aldehydes Chemical class 0.000 description 5
- 238000009833 condensation Methods 0.000 description 5
- 230000005494 condensation Effects 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- 241000224016 Plasmodium Species 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 150000002431 hydrogen Chemical class 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 238000006683 Mannich reaction Methods 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 241000223830 Plasmodium yoelii Species 0.000 description 3
- 150000002466 imines Chemical class 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 229960000901 mepacrine Drugs 0.000 description 3
- INDBQLZJXZLFIT-UHFFFAOYSA-N primaquine Chemical compound N1=CC=CC2=CC(OC)=CC(NC(C)CCCN)=C21 INDBQLZJXZLFIT-UHFFFAOYSA-N 0.000 description 3
- GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- HXEWMTXDBOQQKO-UHFFFAOYSA-N 4,7-dichloroquinoline Chemical compound ClC1=CC=NC2=CC(Cl)=CC=C21 HXEWMTXDBOQQKO-UHFFFAOYSA-N 0.000 description 2
- FQYRLEXKXQRZDH-UHFFFAOYSA-N 4-aminoquinoline Chemical compound C1=CC=C2C(N)=CC=NC2=C1 FQYRLEXKXQRZDH-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- 206010022971 Iron Deficiencies Diseases 0.000 description 2
- 102000002397 Kinins Human genes 0.000 description 2
- 108010093008 Kinins Proteins 0.000 description 2
- 241000224017 Plasmodium berghei Species 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 125000005265 dialkylamine group Chemical group 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000006138 lithiation reaction Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 229960005179 primaquine Drugs 0.000 description 2
- MGCGJBXTNWUHQE-UHFFFAOYSA-N quinoline-4-carbaldehyde Chemical compound C1=CC=C2C(C=O)=CC=NC2=C1 MGCGJBXTNWUHQE-UHFFFAOYSA-N 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- DWZAJFZEYZIHPO-UHFFFAOYSA-N santin Chemical compound C1=CC(OC)=CC=C1C1=C(OC)C(=O)C2=C(O)C(OC)=C(O)C=C2O1 DWZAJFZEYZIHPO-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- FBRBWHYRPDOEFB-UHFFFAOYSA-N 2-methylidene-3-oxocyclopentane-1-carboxylic acid;pyridine-3-carbohydrazide Chemical compound NNC(=O)C1=CC=CN=C1.OC(=O)C1CCC(=O)C1=C FBRBWHYRPDOEFB-UHFFFAOYSA-N 0.000 description 1
- GHCKERHPOQWERJ-UHFFFAOYSA-N 3-aminoacridine Chemical compound C1=CC=CC2=NC3=CC(N)=CC=C3C=C21 GHCKERHPOQWERJ-UHFFFAOYSA-N 0.000 description 1
- PBBGSZCBWVPOOL-HDICACEKSA-N 4-[(1r,2s)-1-ethyl-2-(4-hydroxyphenyl)butyl]phenol Chemical class C1([C@H](CC)[C@H](CC)C=2C=CC(O)=CC=2)=CC=C(O)C=C1 PBBGSZCBWVPOOL-HDICACEKSA-N 0.000 description 1
- WREVVZMUNPAPOV-UHFFFAOYSA-N 8-aminoquinoline Chemical compound C1=CN=C2C(N)=CC=CC2=C1 WREVVZMUNPAPOV-UHFFFAOYSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 150000001414 amino alcohols Chemical group 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000005294 ferromagnetic effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000019256 formaldehyde Nutrition 0.000 description 1
- 229950001996 hexestrol Drugs 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000013110 organic ligand Substances 0.000 description 1
- 238000006146 oximation reaction Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- VFJKXAYBWDJZAE-UHFFFAOYSA-N sodium;cyclopenta-1,3-diene;2-(cyclopenta-2,4-diene-1-carbonyl)benzoic acid;iron(2+) Chemical compound [Na+].[Fe+2].C1C=CC=C1.OC(=O)C1=CC=CC=C1C(=O)[C-]1C=CC=C1 VFJKXAYBWDJZAE-UHFFFAOYSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System
- C07F15/02—Iron compounds
- C07F15/025—Iron compounds without a metal-carbon linkage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System
- C07F15/02—Iron compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F17/00—Metallocenes
- C07F17/02—Metallocenes of metals of Groups 8, 9 or 10 of the Periodic System
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 抗マラリア特性を有する分子に特徴的な少なくとも1つの基本構造、及 び1以上の鉄原子を含有する有機金属鉄錯体、並びに前記錯体の塩、特に酒石酸 若しくは二酒石酸塩。 2. 請求の範囲体1項に記載の錯体であって、これが1以上のフェロセン基 を含有する錯体。 3. 請求の範囲第1項に記載の錯体であって、抗マラリア特性を有する分子 に特徴的な構造要素が、以下のものを含むことを特徴とする錯体。 但し、R1は水素、アルキル、アルコキシ、アシル、ハロゲン又はエーテ ルアルキル アルデヒド、ヒドロキシル、ヒドロキシアルキル、アルコキシアル キル、アシロキシアルキル、アセチルアルキル、好ましくは水素又はエーテルメ チルであり、 R2は水素、アルキル、アルコキシ、ハロゲン、アシル若しくはエーテル アルキル アルデヒド、ヒドロキシル、ヒドロキシアルキル、アルコキシアルキ ル、アシロキシアルキル、アセチルアルキル、好ましくは水素若しくはハロゲン であり、 R3は、共有結合によりフェロセン基に結合されうるアミン又はヒドロキ シアルキル基である。 4. 請求の範囲第3項に記載の錯体であって、これが以下の構造の1つを有 することを特徴とする錯体。 但し、R1は先に定義したとおりである。 5. 請求の範囲第1項から第3項の何れか1項に記載の錯体であって、これ が下記構造を有することを特徴とする錯体。 但し、R1、R2及びR3は請求の範囲第3項で定義したとおりであり、 R4はアルキル、アルコキシ、アシル、ヒドロキシアルキル、アシロキシ アルキル、アセチルアルキル又はフェロセン基であり、 R5は、置換又は無置換アミン基であり、好ましくは1以上のアルキル基 又は1以上のフェロセン基で置換されたものであり、 R10は、水素、アルキル又はアルキル−フェロセン基であり、 R11は、水素又はアルキルである。 6. 請求の範囲第5項に記載の錯体であって、これが下記構造の1つを有す ることを特徴とする錯体。 但し、R2、R4、R10及びR11は先に定義したとおりであり、 R6及びR7は、同じであるか、又は異なっており、水素、アルキル−フ ェロセン、フェロセン、アルキル、特にメチル又はエチルから選択されるが、 キル、アルコキシ、アシル、ハロゲン又はエーテルアルキル アルデヒド、ヒド ロキシル、ヒドロキシアルキル、アルコキシアルキル、アシロキシアル 7. 請求の範囲第1項から第3項の何れか1項に記載の錯体であって、これ が下記構造を有することを特徴とする錯体。 但し、R1及びR2は請求の範囲第3項で定義したとおりであり、R6及 びR7は請求の範囲第5項で定義したとおりである。 8. 請求の範囲第1項から第3の何れか1項に記載の錯体であって、これが 以下の構造を有することを特徴とする錯体。 但し、R6及びR7は請求の範囲第5項で定義したとおりである。 9. マラリアの治療のための組成物であって、これが、請求の範囲第1項か ら第8項で定義した有機金属錯体を、薬学的に許容しうる賦形剤と組み合わせて 含有することを特徴とする組成物。 10. マラリアの治療を意図した医薬の調製のための、請求の範囲第1項か ら第8項の何れか1項に記載の化合物の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9505532A FR2733985B1 (fr) | 1995-05-10 | 1995-05-10 | Complexes organometalliques du fer antipaludiques |
FR95/05532 | 1995-05-10 | ||
PCT/FR1996/000721 WO1996035698A1 (fr) | 1995-05-10 | 1996-05-10 | Complexes organometalliques du fer antipaludiques |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11511738A true JPH11511738A (ja) | 1999-10-12 |
JP4394163B2 JP4394163B2 (ja) | 2010-01-06 |
Family
ID=9478836
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53384296A Expired - Lifetime JP4394163B2 (ja) | 1995-05-10 | 1996-05-10 | 抗マラリア性有機金属鉄錯体 |
Country Status (14)
Country | Link |
---|---|
US (1) | US6127543A (ja) |
EP (1) | EP0824536B1 (ja) |
JP (1) | JP4394163B2 (ja) |
AP (1) | AP953A (ja) |
AT (1) | ATE204581T1 (ja) |
AU (1) | AU718946B2 (ja) |
BR (1) | BR9608473A (ja) |
DE (1) | DE69614679T2 (ja) |
DK (1) | DK0824536T3 (ja) |
ES (1) | ES2163022T3 (ja) |
FR (1) | FR2733985B1 (ja) |
OA (1) | OA10535A (ja) |
PT (1) | PT824536E (ja) |
WO (1) | WO1996035698A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013529597A (ja) * | 2010-06-11 | 2013-07-22 | サノフイ | 集中的還元的アミノ化によるフェロキンの合成方法 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0205455D0 (en) | 2002-03-07 | 2002-04-24 | Molecular Sensing Plc | Nucleic acid probes, their synthesis and use |
FR2952823B1 (fr) | 2009-10-30 | 2012-04-20 | Sanofi Aventis | Utilisation de la ferroquine dans le traitement ou la prevention du paludisme |
FR2951945B1 (fr) | 2009-11-05 | 2013-08-09 | Sanofi Aventis | Composition pharmaceutique |
WO2012104204A1 (en) | 2011-01-31 | 2012-08-09 | Vifor (International) Ag | Iron-carbohydrate complex compounds for the intravenous therapy of malaria |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1470210A (en) * | 1974-10-30 | 1977-04-14 | Edwards E | Organometallic derivatives of penicillin |
DE2815930A1 (de) * | 1978-04-13 | 1979-10-18 | Bayer Ag | Duengemittel zur versorgung von pflanzen mit eisen |
EP0214933A3 (de) * | 1985-09-03 | 1989-05-24 | Ciba-Geigy Ag | Kombinationspräparate zur Behandlung von Malaria |
-
1995
- 1995-05-10 FR FR9505532A patent/FR2733985B1/fr not_active Expired - Lifetime
-
1996
- 1996-05-10 JP JP53384296A patent/JP4394163B2/ja not_active Expired - Lifetime
- 1996-05-10 ES ES96916196T patent/ES2163022T3/es not_active Expired - Lifetime
- 1996-05-10 DE DE69614679T patent/DE69614679T2/de not_active Expired - Lifetime
- 1996-05-10 AP APAP/P/1997/001141A patent/AP953A/en active
- 1996-05-10 WO PCT/FR1996/000721 patent/WO1996035698A1/fr active IP Right Grant
- 1996-05-10 EP EP96916196A patent/EP0824536B1/fr not_active Expired - Lifetime
- 1996-05-10 BR BR9608473-1A patent/BR9608473A/pt not_active IP Right Cessation
- 1996-05-10 PT PT96916196T patent/PT824536E/pt unknown
- 1996-05-10 AT AT96916196T patent/ATE204581T1/de active
- 1996-05-10 AU AU59037/96A patent/AU718946B2/en not_active Expired
- 1996-05-10 US US08/952,093 patent/US6127543A/en not_active Expired - Lifetime
- 1996-05-10 DK DK96916196T patent/DK0824536T3/da active
-
1997
- 1997-11-10 OA OA70125A patent/OA10535A/fr unknown
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013529597A (ja) * | 2010-06-11 | 2013-07-22 | サノフイ | 集中的還元的アミノ化によるフェロキンの合成方法 |
JP2016145214A (ja) * | 2010-06-11 | 2016-08-12 | サノフイ | 集中的還元的アミノ化によるフェロキンの合成方法 |
Also Published As
Publication number | Publication date |
---|---|
AU718946B2 (en) | 2000-05-04 |
WO1996035698A1 (fr) | 1996-11-14 |
ATE204581T1 (de) | 2001-09-15 |
ES2163022T3 (es) | 2002-01-16 |
EP0824536B1 (fr) | 2001-08-22 |
DE69614679D1 (de) | 2001-09-27 |
DK0824536T3 (da) | 2001-12-17 |
PT824536E (pt) | 2002-02-28 |
DE69614679T2 (de) | 2002-06-27 |
AP9701141A0 (en) | 1998-01-31 |
BR9608473A (pt) | 1999-11-30 |
US6127543A (en) | 2000-10-03 |
AU5903796A (en) | 1996-11-29 |
AP953A (en) | 2001-04-02 |
OA10535A (fr) | 2002-04-26 |
FR2733985A1 (fr) | 1996-11-15 |
EP0824536A1 (fr) | 1998-02-25 |
JP4394163B2 (ja) | 2010-01-06 |
FR2733985B1 (fr) | 1997-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Biot et al. | Synthesis and antimalarial activity in vitro of potential metabolites of ferrochloroquine and related compounds | |
US5314894A (en) | (S)-(+)-hydroxychloroquine | |
JP2888485B2 (ja) | 置換9−アミノ−テトラヒドロアクリジンおよび関連化合物 | |
EP1237871A2 (en) | Novel substituted phenanthridinones and methods of use thereof | |
JP2001520629A (ja) | ホスホジエステラーゼ▲iv▼を阻害する化合物および方法 | |
JPH0255438B2 (ja) | ||
JPH06503097A (ja) | 鉄除去のためのヒドロキサメート誘導体を含む製薬組成物 | |
EP2006287B1 (en) | Compound with antimalarial activity and antimalarial drug containing the same as active ingredient | |
JPH11511738A (ja) | 抗マラリア性有機金属鉄錯体 | |
CA2330798C (en) | Febrifugine, isofebrifugine and method for producing the same | |
Dassonville-Klimpt et al. | Mefloquine derivatives: synthesis, mechanisms of action, antimicrobial activities | |
AU2017204652B2 (en) | Treatment of Type I and Type II diabetes | |
EP0785924B1 (fr) | Bis-2-aminopyridines, leur procede de preparation et leurs applications contre les parasitoses | |
US5563149A (en) | Aqueous solutions of pyridone carboxylic acids | |
JPH11507641A (ja) | 多座金属錯体並びにこれらを製造する方法及びこれらの使用 | |
JP3276762B2 (ja) | イソキノリン誘導体を含有する医薬組成物 | |
JP2022515953A (ja) | キノンレダクターゼ2阻害剤化合物およびその使用 | |
JPH06211664A (ja) | 薬剤に対する感受性回復剤 | |
JPH04503216A (ja) | 癲癇およびコカイン嗜癖治療用の5―アミノカルボニル―5H―ジベンゾ〔a,d〕シクロヘプテン―5,10―イミン | |
KR100198489B1 (ko) | 신규 퀴놀론 카르복실산 유도체 및 그 제조방법 | |
RU2409568C2 (ru) | Производные флуорена, обладающие антипролиферативной активностью, модуляторы клеточной дифференцировки, способ замедления скорости пролиферации опухолевых клеток, способ индукции дифференциации в клетках меланомы мышей | |
CA2400394A1 (en) | 9-alkylamino-1-nitroacridine derivatives | |
JPH0331254A (ja) | マラリアの予防及び治療に有用なジスタマイシンa及びその誘導体 | |
FR2694293A1 (fr) | Nouveau dérivé du benzimidazole, son procédé de préparation et les compositions pharmaceutiques qui le contiennent. | |
JPH0641084A (ja) | 5−アミノキノロンカルボン酸誘導体及びこれを有効成分とする抗菌剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060815 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061115 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080408 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080708 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080818 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081008 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090106 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090403 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090915 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20091015 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121023 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131023 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |